METHODS AND COMPOSITIONS RELATING TO P62/SQSTM1 FOR THE TREATMENT AND PREVENTION OF INFLAMMATION-ASSOCIATED DISEASES

(19)

(11)

EP 3 089 753 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 2 (W2 B1)

(48)	Corrigendum issued on:
	28.10.2020 Bulletin 2020/44

(45)	Mention of the grant of the patent:
	26.08.2020 Bulletin 2020/35

(21)	Application number: 14874099.6

(22)	Date of filing: 29.12.2014

(51)

International Patent Classification (IPC):

A61K 38/17^(2006.01)
A61K 39/00^(2006.01)
A61K 31/436^(2006.01)
A61K 31/573^(2006.01)
A61P 37/02^(2006.01)
A61P 25/28^(2006.01)

C07K 14/47^(2006.01)
A61K 45/06^(2006.01)
A61K 31/519^(2006.01)
C12N 15/62^(2006.01)
A61P 37/06^(2006.01)
A61P 29/00^(2006.01)

(86)	International application number:
	PCT/US2014/072484

(87)	International publication number:
	WO 2015/100446 (02.07.2015 Gazette 2015/26)

(54)

METHODS AND COMPOSITIONS RELATING TO P62/SQSTM1 FOR THE TREATMENT AND PREVENTION OF INFLAMMATION-ASSOCIATED DISEASES

VERFAHREN UND ZUSAMMENSETZUNGEN IM ZUSAMMENHANG MIT P62/SQSTM1 ZUR BEHANDLUNG UND PRÄVENTION VON ENTZÜNDUNGSBEDINGTEN ERKRANKUNGEN

MÉTHODES ET COMPOSITIONS RELATIVES À P62/SQSTM1 POUR TRAITER ET PRÉVENIR LES MALADIES ASSOCIÉES À UNE INFLAMMATION

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

29.12.2013 US 201361921504 P
07.03.2014 US 201461949597 P

(43)	Date of publication of application:
	09.11.2016 Bulletin 2016/45

(73)	Proprietor: Curelab Oncology, Inc.
	Dedham MA 02026 (US)

(72)	Inventors:
	VENANZI, Franco 62032 Camerino MC (IT) CONCETTI, Antonio 63837 Falerone FM (IT) SABBIETI, Maria Giovanna 62032 Camerino MC (IT) AGAS, Dimitrios 62032 Camerino MC (IT) GABAI, Vladimir Brighton, Massachusetts 02135 (US) SHIFRIN, Victor Newton, Massachusetts 02466 (US) SHERMAN, Michael Newton, Massachusetts 02459 (US) SHNEIDER, Alexander Needham, Massachusetts 02492 (US)

(74)	Representative: Benatov, Samuil Gabriel
	Dr. EMIL BENATOV & PARTNERS 6, Asen Peykov Str. 1113 Sofia 1113 Sofia (BG)

(56)

References cited: :

WO-A1-2007/044522
WO-A2-2011/039734
US-A- 5 977 311
US-A1- 2009 215 895
US-B1- 6 291 645

WO-A2-2005/050170
CA-A1- 2 844 283
US-A1- 2006 035 823
US-A1- 2012 295 800

GEETHA THANGIAH ET AL: "Sequestosome 1/p62: across diseases", BIOMARKERS : BIOCHEMICAL INDICATORS OF EXPOSURE, RESPONSE, AND SUSCEPTIBILITY TO CHEMI, TAYLOR & FRANCIS, UK, vol. 17, no. 2, 1 March 2012 (2012-03-01), pages 99-103, XP008164216, ISSN: 1366-5804, DOI: 10.3109/1354750X.2011.653986
PARK SANGWOOK ET AL: "p62/SQSTM1 Enhances NOD2-Mediated Signaling and Cytokine Production through Stabilizing NOD2 Oligomerization", PLOS ONE, vol. 8, no. 2, February 2013 (2013-02), XP055384144, ISSN: 1932-6203
SABBIETI MARIA GIOVANNA ET AL: "Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent", ONCOTARGET, vol. 6, no. 6, February 2015 (2015-02), pages 3590-3599, XP055384300,

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).